Pharmacodynamic Effects and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan

A Double-blind, Randomized, Placebo-controlled Phase 1 Study in Healthy Women (#14723)

B. Rohde, C. Seitz, A. Kaiser, M. Schultze-Mosgau, B. Schütt; Bayer Pharma AG, Berlin, Germany
The authors are employees of Bayer Pharma AG.
Vilaprisan (BAY 1002670) has been shown to be a very potent, highly selective progesterone receptor modulator (SPRM) in several *in vitro* and *in vivo* pharmacodynamic (PD) assays (1).

Possible indications of SPRMs include treatment of uterine fibroids (2).

Main symptoms caused by uterine fibroids are menstrual bleeding abnormalities and/or bulk related symptoms.

The efficacy of SPRMs in reduction of menstrual bleeding in both, healthy women and patients with uterine fibroids, has been demonstrated with other SPRMs.

**Aim of the presented study:**
Pharmacodynamic effects, with emphasis on menstrual bleeding, and safety in healthy tubal-ligated women aged 18 to 45 years over a three months treatment

The results of the preceding early phase 1 studies in postmenopausal women following single and daily dosing over 4 weeks supported the conduct of the presented study.

---

(1) Wagenfeld et al., 2013, Human Reproduction, 28 (8): 2253–2264

(2) Bouchard et al., 2011, Fertility and Sterility, 96 (5): 1175-1189
Vilaprisan: PD & Safety Study 14723

Study Design

Healthy tubal-ligated women (aged 18-45 years)
Vilaprisan: PD & Safety Study 14723
Study Parameters

Pharmacodynamics
➢ Impact on bleeding pattern:
   ➢ Primary variable: Non-bleeding rate i.e. number of subjects showing either “no bleeding” or “spotting” during treatment days 10 - 84 (excluding day of biopsy + 2 days)
   ➢ Return of bleeding after end of treatment
➢ Impact on ovarian function:
   ➢ Follicle-Like Structures (FLS) by transvaginal ultrasound
   ➢ Estradiol, progesterone, LH, FSH serum concentrations

Safety
➢ Adverse Events
➢ Endometrial thickness and histology
➢ Vital signs, ECG, standard laboratory parameters

Population Pharmacokinetics/ Pharmacodynamics (Dose-Exposure-Response analysis)
– not presented
Marked and dose-dependent increase in non-bleeding rate. Maximum rate was achieved after ≥ 2 mg vilaprisan with point estimates > 90 %

Upon discontinuation of treatment, return of menstrual bleeding was observed in all women.
Endometrial histology:

- Observed changes in endometrial histology following treatment with vilaprisan imposed similar to those known from other SPRMs, compatible to PAECs (1) (Progesterone Receptor Modulator Associated Endometrial Changes), and were reversible after end of treatment.

- No treatment-emergent critical endometrial findings occurred.

Maximum endometrial thickness:

- No dose-dependent increase and no relevant difference between vilaprisan groups and placebo group.

- Number of subjects with maximum thickness >16 mm did not differ between placebo (4 out of 12 subjects) and vilaprisan groups (0-4 out of 11-12 subjects).

Follicular growth was not suppressed during treatment.

No persistent follicles / ovarian cysts > 28 days observed.

Low progesterone levels (< 1.57 µg/L) indicating for ovulation inhibition/ lack of luteinization were observed in 29 out of 35 women during treatment with ≥ 1mg /d.

---

**Maximum size of Follicle Like Structures (FLS) during treatment (no. of subjects per group)**

<table>
<thead>
<tr>
<th>Group</th>
<th>≤ 13 mm</th>
<th>&gt; 13 ≤ 30 mm</th>
<th>&gt; 30 mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plac. (n = 12)</td>
<td>2</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>0.1 mg (n = 11)</td>
<td>1</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>0.5 mg (n = 11)</td>
<td>0</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>1 mg (n = 12)</td>
<td>1</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>2 mg (n = 12)</td>
<td>0</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>5 mg (n = 11)</td>
<td>1</td>
<td>9</td>
<td>1</td>
</tr>
</tbody>
</table>

---

**Mean progesterone serum concentrations (µg/L) Mean +/- SD**

![Graph showing progesterone levels over time for different groups.](image-url)
None of the subject treated with vilaprisan showed an average E2 level < 40 pg/mL over the 3 months treatment period.
➢ No serious adverse events (SAEs) or AEs that led to premature discontinuation of treatment

➢ Most common drug related AEs (> 5% of subjects) were
  ➢ Headache (19.7% vs 25%; Vilaprisan vs Placebo)
  ➢ Fatigue (11.5% vs 8.3%; Vilaprisan vs Placebo)
  ➢ Ovarian cysts (9.6% vs 0%; Vilaprisan vs Placebo)
  ➢ Abdominal pain (6.8% vs 0%; Vilaprisan vs Placebo)

➢ No clinically relevant changes in vital signs, ECG or standard safety laboratory parameters (incl. e.g. hematology, hemostasis, kidney and liver function)
  ➢ Specifically no increase in aminotransferases (ALT/AST) > 3 x ULN, no hints for drug induced liver injury (1)
Vilaprisan showed dose-dependent pharmacodynamic effects.

The observed reduction of menstrual bleeding in healthy subjects in dosage $\geq 1$ mg/d suggests that vilaprisan is a promising treatment option for uterine fibroids.

Oral administration of vilaprisan for 12 weeks up to 5 mg/d in healthy women aged 18-45 years is considered well tolerated.

The results supported initiation of the currently ongoing Phase 2 study ASTEROID in patients with uterine fibroids.
Vilaprisan PD & Safety Study 14723  
Acknowledgements.

Principal investigators  
Barbara Schütt (Bayer, Clinical Pharmacology Unit)  
Manuela Koch (Nuvisan, Germany)  
David Bell (BioKinetic, UK)  
Grit Andersen (Focus, Germany)  
Wouter Haazen (SGS, Belgium)  
Frank Wagner (Charité Research Organisation, Germany)

And many more ....

Bayer Study Team  
Petra Schulte (Study Manager)  
Andrea Hoehmann (Data Manager)  
Kathrin Machens (Biomarker)  
Esther Groettrup-Wolfers (Pharmacovigilance)
Thank you for your attention
• **Primary variable**: Non-bleeding rate

• Dose-response relationship was estimated using a Bayesian approach

• As dose-response function a 4-parametric sigmoidal $E_{max}$ model was applied (see figure)

• Prior information was incorporated
  ▪ placebo rate from historical studies and literature
  ▪ maximal non-bleeding rate in previous clinical studies with predecessor compound lonaprisan (data on file)
  ▪ $ED_{50}$ as observed in preclinical studies in rabbits with lonaprisan and the marketed SPRM ulipristal (data on file)